|
|
|
|
Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal failure.
Hematide is a relatively small synthetic peptide-based erythropoiesis stimulating agent (ESA), which it is developing for the treatment of anemia patients with chronic renal failure. The Company is conducting Phase III clinical trials in patients suffering from chronic renal renal failure, on dialysis and not on dialysis (pre-dialysis). In August 2008, the Company and Takeda Pharmaceutical Company Limited (Takeda), agreed to suspend development of Hematide to treat chemotherapy induced anemia.
.
( Total: 13 Current Stock Recommendations )
|
|
|
|
Filter by Gains:
Show:
|
Rating:
Sell AFFY
13.98 %
|
|
|
Rating:
Hold AFFY
35.20 %
|
Rating:
Hold AFFY
85.35 %
|
Rating:
Hold AFFY
88.05 %
|
|
|
Rating:
Buy AFFY
91.92 %
|
Rating:
Buy AFFY
81.09 %
|
Rating:
Buy AFFY
75.80 %
|
Rating:
Buy AFFY
75.80 %
|
Rating:
Buy AFFY
79.57 %
|
Rating:
Buy AFFY
79.97 %
|
Rating:
Buy AFFY
75.80 %
|
Rating:
Hold AFFY
1.21 %
|
Rating:
Buy AFFY
94.03 %
|
|
|
|
|
Your Recent Stocks
|
| Symbol | Last | Change |
|
AFFY
| 1.33 |
-6.99 %
|
|
|